Upgrade to SI Premium - Free Trial

bluebird bio (BLUE) Extend Rally as Analysts Reflect Positively on Zynteglo Approval

August 18, 2022 9:15 AM
Shares of Bluebird Bio (NASDAQ: BLUE) are up over 10% today after the United States Food and Drug Administration (FDA) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments FDA Hot Comments Hot List

Next Articles